Zanubrutinib clinical trials
Also written BGB-3111 and Brukinsa.
How each study uses zanubrutinib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the zanubrutinib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 14 Nov 2019 · BRUKINSA · NDA 213217 (FDA, Drugs@FDA)
- European Union
- 22 Nov 2021 · Brukinsa · EMEA/H/C/004978 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
145 studies that test it; most in 2024 (26); 1 more planned to start later
| Year | Studies |
|---|---|
| 2014 | 1 |
| 2016 | 4 |
| 2017 | 7 |
| 2018 | 4 |
| 2019 | 4 |
| 2020 | 15 |
| 2021 | 9 |
| 2022 | 22 |
| 2023 | 17 |
| 2024 | 26 |
| 2025 | 19 |
| 2026 | 17 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 34 · Other 112
BeiGene (28) · Institute of Hematology & Blood Diseases Hospital, China (10) · Ruijin Hospital (10) · BeOne Medicines (6) · Peking University People's Hospital (5) · The First Affiliated Hospital of Soochow University (5) · Peking Union Medical College Hospital (5) · The First Affiliated Hospital with Nanjing Medical University (5)
Often tested with
Tested in the same studies.
Rituximab (30) · Lenalidomide (17) · Obinutuzumab (14) · Bendamustine (9) · Sonrotoclax (7) · Polatuzumab vedotin (6) · Venetoclax (5) · Methotrexate (5)
Related medicines
As reviewed, each with the page that says it.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Tested against it · 2 phase 3 studies under way
Zanubrutinib is the comparator. A study of two new drugs counts under both.
- 1Pirtobrutinib · Loxo Oncology, Inc. · next primary completion Nov 2027
- 1Rocbrutinib · Guangzhou Lupeng Pharmaceutical Company LTD. · next primary completion May 2031
Reaching primary completion within a year · 29, 2 in phase 3
Studies that test zanubrutinib, phase 3 first.
- Dec 2026A Study to Evaluate Long-term Safety of Zanubrutinib Regimens in Participants With B-Cell Malignancies Who Participated in BeiGene Parent Studies of ZanubrutinibPhase 3 · BeOne Medicines
- Oct 2027A Study to Examine the Efficacy and Safety of Zanubrutinib Given to Adults With Primary Membranous NephropathyPhase 2/3 · BeOne Medicines
- Nov 2026Zanubrutinib-based Maintenance Therapy of Newly Diagnosed DLBCL With Initial RemissionPhase 2 · Ruijin Hospital
- Nov 2026Zanubrutinib Combined With BEAM for ASCT in Relapsed and Refractory DLBCLPhase 2 · Ruijin Hospital
- Nov 2026Zanubrutinib Plus BR in Newly Diagnosed Symptomatic WMPhase 2 · Institute of Hematology & Blood Diseases Hospital, China
- Dec 2026Zanubrutinib, Obinutuzumab and Lenalidomide (ZGR) in High-risk Treatment-naive Patients with Follicular Lymphoma (FL)Phase 2 · Ruijin Hospital
- Dec 2026Zanubrutinib, Bendamustine, Rituximab Prev. Untreated WMPhase 2 · Massachusetts General Hospital
- Dec 2026Combination of Zanubrutinib, Rituximab and Venetoclax in Patients With Previously Untreated Follicular LymphomaPhase 2 · Chinese PLA General Hospital
- Dec 2026Zanubrutinib Plus Rituximab as Front-line Treatment for Mucosa-associated Lymphoid Tissue Lymphoma (MALT)Phase 2 · Sun Yat-sen University
- Dec 2026Obinutuzumab, Zanubrutinib, and Lenalidomide Followed Short-Cycle of Obinutuzumab and Cytarabine in Newly Diagnosed Mantle Cell LymphomaPhase 2 · Institute of Hematology & Blood Diseases Hospital, China
Studies
Open first, then newest update. How each study uses zanubrutinib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 146
- Zanubrutinib, Bendamustine, Rituximab Prev. Untreated WMRecruitingPhase 2Massachusetts General HospitalNCT06561347Written as Zanubrutinib
- Optimal Dose of Zanubrutinib to Treat Adult Immune ThrombocytopeniaNot yet recruitingPhase 2Peking University People's HospitalNCT07315373Written as Zanubrutinib 80mg/d
- Zanubrutinib Plus Lenalidomide for Frail Elderly Patients With Newly Diagnosed PCNSLRecruitingPhase 2Xiaohui RenNCT07839247Written as Zanubrutinib
- Venetoclax Plus Zanubrutinib for the Treatment of Chronic Lymphocytic Leukemia and Small Lymphocytic LymphomaRecruitingPhase 2Kerry RogersNCT07734038Written as Zanubrutinib
- MACE and BTK InhibitorsNot yet recruitingPhase 4University Hospital, CaenNCT07923162Written as Zanubrutinib
- Zanubritnib and Anti-MAG NeuropathyRecruitingPhase 2Azienda Ospedaliera di PadovaNCT07392229Written as Zanubrutinib Oral Capsule
- A Study of Zanubrutinib, Obinutuzumab, and Sonrotoclax in People With Mantle Cell LymphomaNot yet recruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT07799220Written as Zanubrutinib
- Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell LymphomaRecruitingPhase 3Alliance for Clinical Trials in OncologyNCT05976763Written as Zanubrutinib
- A Trial to Evaluate the Efficacy and Safety of a Fitness-adapted Thera-py Approach With Either Continuous Zanubrutinib Monotherapy or Time-limited Zanubrutinib + Sonrotoclax in Older and/or Frail Patients With Treatment-naïve CLLNot yet recruitingPhase 2German CLL Study GroupNCT07899398Written as Zanubrutinib
- Glofitamab, Polatuzumab Vedotin and Zanubrutinib in First-line Elderly DLBCLRecruitingPhase 2Shanghai Zhongshan HospitalNCT07012980Written as Zanubrutinib
- Sonrotoclax Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma Planned for Standard of Care CAR-T Cell TherapyRecruitingPhase 2Canadian Cancer Trials GroupNCT07341191Written as Zanubrutinib
- A Phase 2 Trial of Mosunetuzumab and Zanubrutinib for Patients With Relapsed/Refractory Marginal Zone LymphomaRecruitingPhase 2M.D. Anderson Cancer CenterNCT06563505Written as Zanubrutinib
- Rituximab and Zanubrutinib in Patients With Indolent B-cell LymphomasRecruitingPhase 2H. Lee Moffitt Cancer Center and Research InstituteNCT06350318Written as Zanubrutinib
- A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic LeukemiaRecruitingPhase 3BeOne MedicinesNCT07277231Written as Zanubrutinib
- Epco, Zanu, Ritux for R/R FL or MZLRecruitingPhase 2Reid Merryman, MDNCT06563596Written as Zanubrutinib
- Zanubrutinib and Tafasitamab in Mantle Cell LymphomaRecruitingPhase 1/2Alvaro Alencar, MDNCT06029309Written as Zanubrutinib
- Zanubrutinib in Combination With Odronextamab for the Treatment of Patients With Richter's TransformationRecruitingPhase 1City of Hope Medical CenterNCT06735664Written as Zanubrutinib
- Study of Zanubrutinib in Older Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL)Not yet recruitingPhase 2The Lymphoma Academic Research OrganisationNCT07739459Written as Zanubrutinib
- Zanubrutinib and Sonrotoclax for the Treatment of Relapsed Chronic Lymphocytic Leukemia /Small Lymphocytic Leukemia, ZeuS-2 TrialNot yet recruitingPhase 2City of Hope Medical CenterNCT07812246Written as Zanubrutinib
- ZR-MTX for PIOL Phase II TrialRecruitingPhase 2Peking Union Medical College HospitalNCT06973811Written as Zanubrutinib
See all 146 studies that test zanubrutinib →
Given beside what is tested · 33 — zanubrutinib is usual care or a partner of the new treatment
- Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLLRecruitingPhase 3Alliance for Clinical Trials in OncologyNCT07321652Written as Zanubrutinib
- A Randomized Phase II Study Of Bruton Tyrosine Kinase Inhibitor With Or Without Venetoclax In Veterans With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)RecruitingPhase 2VA Office of Research and DevelopmentNCT06520098Written as Ibrutinib, Acalabrutinib, Zanubrutinib
- Sonrotoclax, Rituximab, and Zanubrutinib in Treating Participants With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Mantle Cell LymphomaRecruitingPhase 2Fred Hutchinson Cancer CenterNCT06839053Written as Zanubrutinib
- A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)RecruitingPhase 3BeOne MedicinesNCT06742996Written as Zanubrutinib
- Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to TreatmentRecruitingPhase 2SWOG Cancer Research NetworkNCT05890352Written as Zanubrutinib
- A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.RecruitingPhase 1/2BeOne MedicinesNCT06697184Written as Zanubrutinib
- Testing Mosunetuzumab Alone, With Zanubrutinib, or With Polatuzumab Vedotin for Treating Marginal Zone Lymphoma That Came Back or Didn't Get Better With TreatmentNot yet recruitingPhase 2SWOG Cancer Research NetworkNCT07638722Written as Zanubrutinib
- A Study to Investigate Safety and Effectiveness of Tacabrutideg (BGB-16673) in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell MalignanciesRecruitingPhase 1/2BeOne MedicinesNCT06634589Written as Zanubrutinib
- Zanubrutinib, Obinutuzumab, Sonrotoclax (BOSon) or BGB-16673, Obinutuzumab, Sonrotoclax (DOSon) in TN CLL/SLLRecruitingPhase 2Massachusetts General HospitalNCT06849713Written as Zanubrutinib
- A Study of Mosunetuzumab Alone or With Zanubrutinib in People With Follicular LymphomaRecruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT05389293Written as Zanubrutinib
- AI-Driven Treatment Strategy vs ZR2 in Older Treatment-naive Patients With LBCLNot yet recruitingPhase 2Ruijin HospitalNCT07717177Written as Zanubrutinib
- Phase II Study of Glofitamab With Venetoclax +/- Zanubrutinib in High-risk Mantle-cell LymphomaRecruitingPhase 2The Lymphoma Academic Research OrganisationNCT06558604Written as Zanubrutinib Oral Capsule
- A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell MalignanciesRecruitingPhase 2Curis, Inc.NCT07271667Written as Zanubrutinib
- The Efficacy and Safety of Sonrotoclax, Zanubrutinib Combined With Obinutuzumab in MCLNot yet recruitingPhase 1Ruijin HospitalNCT07548255Written as Sonrotoclax, Zanubrutinib Combined with Obinutuzumab
- Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin LymphomaRecruitingPhase 1City of Hope Medical CenterNCT06859008Written as Zanubrutinib
- Mosunetuzumab for CLL MRD ClearanceRecruitingPhase 1/2Inhye AhnNCT07052695Written as Zanubrutinib
- Study Evaluating the Efficacy and Tolerance of a Zanubrutinib and BGB-11417 Combination in Patients Previously Treated for Waldenström MacroglobulinemiaNot yet recruitingPhase 2French Innovative Leukemia OrganisationNCT06547866Written as zanubrutinib + BGB-11417
- A Study of GFH009 in Combination With Zanubrutinib in Subjects With Relapsed or Refractory DLBCLRecruitingPhase 1/2Genfleet Therapeutics (Shanghai) Inc.NCT06375733Written as Zanubrutinib
- Sonrotoclax, Zanubrutinib and CD20mab in Untreated MCL PatientsRecruitingPhase 2Tianjin Medical University Cancer Institute and HospitalNCT06463691Written as BGB-3111
- Immunobridging/Maintenance Therapy Versus Non-bridging Therapy in CAR-T Therapy for Low-risk R/R B-NHLRecruitingPhase 2Ruijin HospitalNCT06695013Written as zanubrutinib
Showing 20 of 33.
As the comparator · 4 — what is tested is compared with zanubrutinib
- Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic LymphomaRecruitingPhase 2National Cancer Institute (NCI)NCT04840602Written as Zanubrutinib
- A Study of Rocbrutinib Versus Investigator's Choice of BTK Inhibitors in Patients With Relapsed or Refractory Mantle Cell LymphomaRecruitingPhase 3Guangzhou Lupeng Pharmaceutical Company LTD.NCT07377578Written as Zanubrutinib
- Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)Active, not recruitingPhase 3Loxo Oncology, Inc.NCT04662255Written as Zanubrutinib
- A Study Comparing BGB-3111 and Ibrutinib in Participants With Waldenström's Macroglobulinemia (WM)CompletedPhase 3BeiGeneNCT03053440Written as BGB-3111
What changed recently
From the registry's own updates since Oct 18, 2026.
Newly registered2
Codes
What other systems call zanubrutinib · ClinicalTrials.gg INT001030
- MeSH (NLM) C000629551zanubrutinibConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) AG9MHG098ZZANUBRUTINIBConfirmed FDA, NLM, Wikidata
- RxNorm 2262435One source FDA
- Wikidata Q75192022zanubrutinibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C141428ZanubrutinibOne source FDA
- DrugBank DB15035One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000629551 | zanubrutinib | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | AG9MHG098Z | ZANUBRUTINIB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2262435 | — | One source FDA |
| Wikidata | Q75192022 | zanubrutinib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C141428 | Zanubrutinib | One source FDA |
| DrugBank | DB15035 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.